← Back to headlines
Apnimed, Backed by Shionogi, Raises $192 Million in US IPO
Apnimed, a biotech company supported by Shionogi and focused on a pill for sleep apnea, successfully raised $192 million in its U.S. Initial Public Offering.
31 Jul, 02:21 — 31 Jul, 02:24
The Story
Analyzing sources…
Source Diversity
Source Diversity
Low (19/100)2 sources— more sources would strengthen this score15/33
Spectrum spread— 1/5 buckets covered0/33
Far L
Left
Center2
Center (2)
bloombergforbes
Right
Far R
Geographic diversity— 1 region4/34
US2
ℹAll sources from US region
ℹOnly 2 sources cover this story
Sources
Showing 2 of 2 sources
bloombergHigh11h ago
Shionogi-Backed Biotech Apnimed Raises $192 Million in US IPO
Apnimed Inc., a late-stage drug developer focused on sleep apnea, raised $192 million in an upsized US initial public offering, priced at the top of a marketed range.
By Angel Adegbesan
Read full article →forbes11h ago
The Startup Behind The Pill For Sleep Apnea Raises $192 Million In IPO
Apnimed got a new CEO in anticipation of its public offering. Its pill for sleep apnea could receive approval early next year.
By Amy Feldman, Forbes Staff
Read full article →Coverage Timeline
First report: forbes · 31 Jul, 02:21|Full coverage: 2 · 2m|Window: 2m
Left-leaningCenterRight-leaning
